Healthcare - Biotechnology - NASDAQ - US
$ 6.12
-3.32 %
$ 647 M
Market Cap
-5.06
P/E
CASH FLOW STATEMENT
-121 M
OPERATING CASH FLOW
70.7 M
INVESTING CASH FLOW
136 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Annexon, Inc.
| Net Income | -134 M |
| Depreciation & Amortization | 2.15 M |
| Capital Expenditures | -193 K |
| Stock-Based Compensation | 18.2 M |
| Change in Working Capital | -5.8 M |
| Others | -5.16 M |
| Free Cash Flow | -121 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (134.2) | (141.9) | (130.3) | (63.4) | (37.2) | (18.3) | (18.7) |
| Depreciation & Amortization | 2.1 | 2.1 | 2.1 | 0.7 | 0.5 | 0.5 | 0.3 |
| Deferred Income Tax | 0 | 0 | 1.3 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 18.2 | 18.5 | 16.3 | 4.9 | 2.0 | 0.4 | 0.4 |
| Other Operating Activities | (1.4) | 1.3 | 1.3 | 53 K | 5.7 | (0.3) | 0.8 |
| Change in Working Capital | (5.8) | 3.7 | 3.3 | 4.7 | 0.6 | 0.5 | (1.2) |
| Cash From Operations | (121.1) | (116.3) | (106.1) | (53.1) | (28.4) | (17.2) | (19.3) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.2) | (6.5) | (1.7) | (0.5) | (0.3) | 17 K | (0.6) |
| Other Items | 70.9 | 65.0 | (86.6) | (82.7) | 0 | 0 | 0 |
| Cash From Investing Activities | 70.7 | 58.4 | (88.2) | (83.2) | (0.3) | 17 K | (0.6) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (6.2) | 0 | 0 | 0 |
| Other Financing Activities | 14 K | (7.6) | 1.8 | 100.1 | 28.4 | 58.5 | 42 K |
| Cash From Financing Activities | 135.5 | 122.9 | 1.8 | 360.9 | 28.4 | 58.5 | 42 K |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 85.1 | 65.0 | (192.6) | 224.6 | (0.2) | 41.2 | (19.8) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (121.3) | (122.8) | (107.8) | (53.6) | (28.6) | (17.2) | (19.8) |